Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reconciliation Consolidated Net Loss (Details)

v3.26.1
Schedule of Reconciliation Consolidated Net Loss (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Product Cost of Sales
Gross Income
Operating Expenses    
Administrative Expenses 3,736,525 4,161,907
Research and Development Expenses 3,471,841 3,441,010
Adjustments and Reconciling Items    
Stock Based Compensation 2,174,524 1,057,271
Series F-1 Warrant Issuance Expenses 539,097
Series G Warrant Issuance Expenses 969,505
Series H Warrant Issuance Expenses 264,417
Interest and Dividend Income 225,388 351,809
Gains on Sales of Marketable Securities 2,176 976
Unrealized Gains on Marketable Securities 38,671 671
Change in Fair Value of Derivative Liabilities 983,000 (388,000)
Change in Fair Value of Warrant Liabilities (4,410,000)
Loss on Issuance of Series G Convertible Preferred Stock (5,109,000)
Casualty Gain/(Loss) 100,000
Total Adjustments and Reconciling Items (1,779,765) (13,190,544)
Net Loss (11,627,122) (23,359,334)
Pharmaceuticals Segment [Member]    
Segment Reporting Information [Line Items]    
Product Cost of Sales
Gross Income
Operating Expenses    
Administrative Expenses 2,013,710 4,161,907
Research and Development Expenses 3,045,977 3,441,010
Stock-Based Compensation 1,937,691
Franchise Tax Expense 150,038
Warrant Issuance Expense
Segment Net Loss (7,147,415) (7,602,917)
Adjustments and Reconciling Items    
Stock Based Compensation 1,325,144 1,057,271
Series F Warrant Issuance Expenses
Series F-1 Warrant Issuance Expenses 539,097
Series G Warrant Issuance Expenses 969,505
Series H Warrant Issuance Expenses
Dividends Paid on Series H Preferred Stock
Interest and Dividend Income 156,042 351,809
Gains on Sales of Marketable Securities 2,176 976
Unrealized Gains on Marketable Securities (1,435) 671
Change in Fair Value of Derivative Liabilities 1,303,000 (388,000)
Change in Fair Value of Warrant Liabilities (4,410,000)
Loss on Issuance of Series F-1 Convertible Preferred Stock (3,737,000)
Loss on Issuance of Series G Convertible Preferred Stock (5,109,000)
Loss on Impairment of Intangible (1,500,000)
Loss on FMV of Contingent Compensation
Casualty Gain/(Loss) 100,000
Total Adjustments and Reconciling Items (1,365,331) (15,756,417)
Net Loss (5,782,084) (23,359,334)
Computing Technology Segment [Member]    
Segment Reporting Information [Line Items]    
Product Cost of Sales
Gross Income
Operating Expenses    
Administrative Expenses 1,722,816
Research and Development Expenses 425,864
Stock-Based Compensation 236,833  
Franchise Tax Expense 50,013
Warrant Issuance Expense 264,417
Segment Net Loss (2,699,942)
Adjustments and Reconciling Items    
Stock Based Compensation
Series F Warrant Issuance Expenses
Series F-1 Warrant Issuance Expenses
Series G Warrant Issuance Expenses
Series H Warrant Issuance Expenses 264,417
Dividends Paid on Series H Preferred Stock 99,437
Interest and Dividend Income 69,346
Gains on Sales of Marketable Securities
Unrealized Gains on Marketable Securities 40,106
Change in Fair Value of Derivative Liabilities (320,000)
Change in Fair Value of Warrant Liabilities
Loss on Issuance of Series F-1 Convertible Preferred Stock
Loss on Issuance of Series G Convertible Preferred Stock
Loss on Impairment of Intangible
Loss on FMV of Contingent Compensation (1,529,000)
Casualty Gain/(Loss)
Total Adjustments and Reconciling Items (2,103,402)
Net Loss $ (596,540)